← Back to headlines
Citi Maintains 'Buy' Rating for AstraZeneca Ahead of Q2 Results
Citi has reiterated its 'buy' rating for pharmaceutical giant AstraZeneca as the company approaches its second-quarter earnings report.
6 Jul, 12:03 — 6 Jul, 12:03
Sources
Showing 1 of 1 sources
